Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Steven Cohen Takes a Big Position in Arrowhead Research

SAC Capital, Cohen, Arrowhead Research: Steven Cohen‘s SAC Capital just disclosed a 5.2% passive stake in Arrowhead Research Corp (NASDAQ:ARWR), a bio-therapeutics company that specializes in nanomedicine.


Generally speaking, Cohen and SAC like small pharmaceutical companies. Amid the negative headlines that his insider trading trial is drawing (he’s even selling some of his art!), it appears that Cohen and his team are still doing work to find undervalued investment opportunities in the small-cap space.

As mentioned above, Arrowhead Research specializes in nanomedicine, and from its business description, it focuses on “products at the interface of biology and nano-engineering to cure disease and improve human health.” More specifically, Arrowhead focuses on therapeutic products that can be used to battle various cancers and obesity, and specific types of its nanomedicines can be used to regenerate tissue.

Within the company’s asset portfolio, RNA-gene silencing treatment is also in development.

Disclosure: none

Recommended Reading:

Is This the End of Steven Cohen’s Insider Trading Battle?

SAC Capital, Citadel and Others Received Apple-Related Information Leak Last Year

Steven Cohen, SAC Capital’s Stake in SunEdison Surges